SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD
(Incorporated in Bermuda on 26 April 2006)
(Company Registration Number: 38317)
The Company was incorporated in Bermuda on 26 April 2006 under the Bermuda Companies Act as an exempted company with limited liability under the name of Sihuan Pharmaceutical Holdings Group Ltd. Headquartered in Haikou, Hainan Province with manufacturing facilities located in Beijing, the Group is specialized in the field of cardiocerebral vascular drugs.
The principal business activities can be categorized as follows: The Group undertakes the R&D, production and/or sale of cardiocerebral vascular drugs in the PRC, which is the core business activity. The Group's cardiocerebral vascular drugs are used for the treatment of a wide range of cardiocerebral vascular diseases, such as coronary heart disease, pneumocardial disease, cerebrovascular disease, rheumatic fever, chronic rheumatic heart disease, atheroma, hypertension and embolism.
The Group also undertakes the R&D, production and/or sale of non-cardiocerebral vascular drugs. The non-cardiocerebral vascular drugs include those used for the treatment of cancer, infections caused by bacteria, refractory infections from tuberculosis, chronic respiratory diseases, prevention and treatment of chronic hepatitis and hepatic cirrhosis.
As at January 2007, the Group markets and sells 13 cardiocerebral vascular drugs and 18 noncardiocerebral vascular drugs in different forms and dosages. Through its in-house R&D team in Haikou City, Hainan, and Beijing, as well as through joint collaborations with renowned third-party research institutions, academic bodies and pharmaceutical research companies, the Group is in the process of developing or procuring the development of more than 50 pharmaceutical products which are at various stages of development.
(Incorporated in Bermuda on 26 April 2006)
(Company Registration Number: 38317)
The Company was incorporated in Bermuda on 26 April 2006 under the Bermuda Companies Act as an exempted company with limited liability under the name of Sihuan Pharmaceutical Holdings Group Ltd. Headquartered in Haikou, Hainan Province with manufacturing facilities located in Beijing, the Group is specialized in the field of cardiocerebral vascular drugs.
The principal business activities can be categorized as follows: The Group undertakes the R&D, production and/or sale of cardiocerebral vascular drugs in the PRC, which is the core business activity. The Group's cardiocerebral vascular drugs are used for the treatment of a wide range of cardiocerebral vascular diseases, such as coronary heart disease, pneumocardial disease, cerebrovascular disease, rheumatic fever, chronic rheumatic heart disease, atheroma, hypertension and embolism.
The Group also undertakes the R&D, production and/or sale of non-cardiocerebral vascular drugs. The non-cardiocerebral vascular drugs include those used for the treatment of cancer, infections caused by bacteria, refractory infections from tuberculosis, chronic respiratory diseases, prevention and treatment of chronic hepatitis and hepatic cirrhosis.
As at January 2007, the Group markets and sells 13 cardiocerebral vascular drugs and 18 noncardiocerebral vascular drugs in different forms and dosages. Through its in-house R&D team in Haikou City, Hainan, and Beijing, as well as through joint collaborations with renowned third-party research institutions, academic bodies and pharmaceutical research companies, the Group is in the process of developing or procuring the development of more than 50 pharmaceutical products which are at various stages of development.
No comments:
Post a Comment